Access

Sanofi-aventis: Impact Epilepsy Program for Developing Countries

Sanofi-aventis, one of the major actors in the fight against epilepsy in the developed world, is also committed to the treatment of epilepsy worldwide using its two major treatments, Gardenal and, more importantly, Depakine / valproate Winthrop within a tiered pricing policy. In Mali, sanofi-aventis is working with Sant Sud and the Association des Medecins de Campagne (AMC) which have created the Reseau Action Recherche contre l'Epilepsie (RARE).

Sanofi-aventis Sleeping Sickness Program

Sleeping sickness has reemerged in Africa as a major health threat. In 2001, sanofi-aventis committed USD 25 million over the years 2001-2006 to help the World Health Organization (WHO) to implement a strategy of adequate medicine supplies, disease surveillance and management, plus R&D for new treatments. After five years, WHO and sanofi-aventis' efforts were estimated to have saved 110,000 lives. In 2006, the company renewed its contract with the WHO and expanded it to address several additional 'most neglected diseases' (see separate entry).

Sanofi-aventis Children's Programs

Sanofi-aventis supports a number of projects in developing countries, the main purpose of which is to help improve children's health.

Sanofi-aventis 'Most Neglected Diseases' Program

As part of its 5-year agreement with the World Health Organization (WHO) in 2006 to extend its partnership in sleeping sickness (see separate entry), sanofi-aventis also undertook to support a collaborative program with WHO to improve treatment for some 'most neglected diseases', namely leishmaniasis, Chagas disease and Buruli ulcer. Sanofi-aventis is providing USD 6.4 million to WHO over 5 years for development of training, diagnostics and optimization of treatment for leishmaniasis.

Sanofi-aventis - DNDi Malaria Medicine

In April 2005, sanofi-aventis signed an agreement with Drugs for Neglected Diseases initiative (DNDi) to develop a new medicine against malaria, in response to a call from the World Health Organization (WHO) for malaria be treated by drug combinations to combat resistance. DNDi and sanofi-aventis have developed a fixed-dose combination (FDC) of two antimalarial compounds, artesunate and amodiaquine (ASAQ) that is easier to use and more affordable than any other combination currently available.

Rotavirus Vaccine Program

The Rotavirus Vaccine Program works to accelerate the introduction of new vaccines to treat rotavirus.

Roll Back Malaria Partnership

To provide a coordinated global approach to fighting malaria, the Roll Back Malaria (RBM) Partnership was launched in 1998 by the World Health Organization (WHO), the United Nations Children's Fund (UNICEF), the United Nations Development Programme (UNDP) and the World Bank.

Roche - Access to ARVs

In 2002, Roche recognized that, as efforts to scale up the number of people on first-line therapy in resource-limited countries became successful and greater numbers of people received treatment, the need for second-line treatment options would also become increasingly important. In response, Roche committed to innovative, transparent policies to remove barriers to its second-line HIV protease inhibitor medicines in countries where resources are fewest and the need for treatment is greatest.

Pneumococcal Conjugate Vaccine Programs

Pneumococcal disease takes the lives of 1.6 million people each year, including approximately 800,000 children before their fifth birthday. More than 90% of these deaths occur in developing countries. Its most common serious form, pneumonia, accounts for one in every four child deaths. GlaxoSmithKline and Pfizer have developed pneumococcal conjugate vaccines which protect against this major health threat.

PMTCT: Abbott Rapid HIV Test Donation Program

Each year, approximately 800,000 babies around the world become infected with HIV during their mothers´ pregnancy, during birth or through breastfeeding.

Pages